Recombinant MBP-pσ1 expressed in soybean seeds delays onset and reduces developing disease in an animal model of multiple sclerosis

• Published in: Plant Biotechnology Vol. 39; no. 4; pp. 367 - 379
• Main Authors: Robles, Linda M., Reichenberg, Laura H., Ⅲ, James H. Grissom, Chi, Richard J., Piller, Kenneth J.
• Format: Journal Article
• Language: English
• Published: Japan Japanese Society for Plant Biotechnology 25.12.2022; Japan Science and Technology Agency
• Subjects: Animal diseases; Animal models; Antigens; Autoantigens; Autoimmune diseases; Autoimmunity; Disease; Epitopes; Experimental allergic encephalomyelitis; experimental autoimmune encephalomyelitis (EAE); Immunomodulation; M cells; Multiple sclerosis; multiple sclerosis (MS); Myelin; Myelin basic protein; myelin basic protein (MBP); Original Paper; Peptides; Proteins; reovirus protein sigma1 (pσ1); Seeds; Soya bean milk; Soybean milk; Soybeans; transgenic soybean; Viruses; multiple sclerosis (MS); reovirus protein sigma1 (pσ1); myelin basic protein (MBP); experimental autoimmune encephalomyelitis (EAE); transgenic soybean
• ISSN: 1342-4580; 1347-6114
• DOI: 10.5511/plantbiotechnology.22.0926a

It is estimated that multiple sclerosis (MS) affects over 2.8 million people worldwide, with a prevalence that is expected to continue growing over time. Unfortunately, there is no cure for this autoimmune disease. For several decades, antigen-specific treatments have been used in animal models of experimental autoimmune encephalomyelitis (EAE) to demonstrate their potential for suppressing autoimmune responses. Successes with preventing and limiting ongoing MS disease have been documented using a wide variety of myelin proteins, peptides, autoantigen-conjugates, and mimics when administered by various routes. While those successes were not translatable in the clinic, we have learned a great deal about the roadblocks and hurdles that must be addressed if such therapies are to be useful. Reovirus sigma1 protein (pσ1) is an attachment protein that allows the virus to target M cells with high affinity. Previous studies showed that autoantigens tethered to pσ1 delivered potent tolerogenic signals and diminished autoimmunity following therapeutic intervention. In this proof-of-concept study, we expressed a model multi-epitope autoantigen (human myelin basic protein, MBP) fused to pσ1 in soybean seeds. The expression of chimeric MBP-pσ1 was stable over multiple generations and formed the necessary multimeric structures required for binding to target cells. When administered to SJL mice prophylactically as an oral therapeutic, soymilk formulations containing MBP-pσ1 delayed the onset of clinical EAE and significantly reduced developing disease. These results demonstrate the practicality of soybean as a host for producing and formulating immune-modulating therapies to treat autoimmune diseases.